Table 1 Patient and transplant characteristics.

From: Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Variable

Entire cohort

FluMel

FBM/FTM

p-value

N (%)

1272 (100)

1002 (79%)

270 (21%)

 

Year of allo-HCT

  ‐ median (range)

2017 (2009–2020)

2017 (2009–2020)

2017 (2009–2020)

0.71

  ‐ IQR

2015–2019

2015–2019

2016–2018

 

Median Follow-up

2.3

2.6

2.0

 

(years) [95%CI]

[2.1–2.7]

[2.2–2.9]

[1.6–2.2]

 

Conditioning (%)

  ‐ FluMel

1002 (79%)

1002 (100%)

  

  ‐ FBM

220 (17%)

 

220 (81%)

 

  ‐ FTM

50 (4%)

 

50 (19%)

 

Melphalan dose

  ‐ median (range)

140 (110–144.4)

140 (135–144.4)

110 (110–115)

<0.001

  ‐ [IQR]

[138.4–140]

[140–140]

[110–110]

 

BCNU dose (for FBM)

  ‐ 300 mg/m2

218 (99%)

 

218 (99%)

 

  ‐ 400 mg/m2

2 (1%)

 

2 (1%)

 

Thiotepa dose (for FTM)

  ‐ 10 mg/kg

35 (70%)

 

35 (70%)

 

  ‐ 5 mg/kg

15 (30%)

 

15 (30%)

 

Patient age (years)

   

<0.001

median (min-max)

61.2 (20.5–76.4)

59.8 (21.1–75.2)

64.1 (20.5–76.4)

 

 [IQR]

[54.4–65.5]

[52.5–64.8]

[60.4–66.9]

 

Age group

   

<0.0001

  ‐ age <61 years

629 (49%)

555 (55%)

74 (27%)

 

  ‐ age ≥61 years

643 (51%)

447 (45%)

196 (73%)

 

KPS score

   

0.0034

  ‐ <90

302 (25%)

218 (24%)

84 (33%)

 

  ‐ ≥90

881 (75%)

707 (76%)

174 (67%)

 

  ‐ missing

89

77

12

 

Patient sex

   

0.69

  ‐ female

567 (45%)

444 (44%)

123 (46%)

 

  ‐ male

703 (55%)

557 (56%)

146 (54%)

 

  ‐ missing

2

1

1

 

Donor sex

   

0.72

  ‐ female

404 (32%)

321 (32%)

83 (31%)

 

  ‐ male

859 (68%)

675 (68%)

184 (69%)

 

  ‐ missing

9

6

3

 

Female to male combination

   

0.1

  ‐ No

1064 (84%)

830 (83%)

234 (87%)

 

  ‐ Yes

202 (16%)

168 (17%)

34 (13%)

 

  ‐ missing

6

4

2

 

AML diagnosis

   

0.0025

  ‐ de novo

1078 (85%)

865 (86%)

213 (79%)

 

  ‐ secondary AML

194 (15%)

137 (14%)

57 (21%)

 

Cytogenetics

   

0.96

  ‐ intermediate

958 (75%)

755 (75%)

203 (75%)

 

  ‐ adverse

314 (25%)

247 (25%)

67 (25%)

 

Patient CMV

   

0.95

  ‐ neg

477 (38%)

375 (38%)

102 (38%)

 

  ‐ pos

786 (62%)

619 (62%)

167 (62%)

 

  ‐ missing

9

8

1

 

Donor CMV

   

0.54

  ‐ neg

632 (50%)

503 (51%)

129 (49%)

 

  ‐ pos

623 (50%)

487 (49%)

136 (51%)

 

  ‐ missing

17

12

5

 

Donor type

   

<0.001

  ‐ MSD

397 (31%)

345 (34%)

52 (19%)

 

  ‐ UD

875 (69%)

657 (66%)

218 (81%)

 

Donor type

   

<0.001

  ‐ MSD

397 (31%)

345 (34%)

52 (19%)

 

  ‐ UD 10/10

465 (37%)

379 (38%)

86 (32%)

 

  ‐ UD 9/10

92 (7%)

73 (7%)

19 (7%)

 

  ‐ UD missing/ incomplete HLA

318 (25%)

205 (20%)

113 (42%)

 

GvHD prophylaxis

   

n.d.

  ‐ CsA

719 (57%)

704 (70%)

15 (6%)

 

  ‐ CsA + MMF

297 (23%)

109 (11%)

188 (70%)

 

  ‐ CsA + MTX

127 (10%)

106 (11%)

21 (8%)

 

  ‐ Other

126 (10%)

82 (8%)

44 (16%)

 

  ‐ missing

3

1

2

 

In vivo TCD

  ‐ no in vivo TCD

102 (8%)

77 (8%)

25 (9%)

0.39*

  ‐ in vivo TCD

1168 (92%)

924 (92%)

244 (91%)

 

  ‐ ATG

401 (32%)

179 (18%)

222 (82%)

<0.001**

  ‐ alemtuzumab

767 (60%)

745 (74%)

22 (9%)

 

  ‐ missing

2

1

1

 
  1. FluMel fludarabine/melphalan, FBM fludarabine/BCNU/melphalan, FTM fludarabine/thiotepa/melphalan, Allo-HCT allogeneic hematopoietic cell transplantation, MSD matched sibling donor, UD unrelated donor, HLA human leukocyte antigen, AML acute myeloid leukemia, KPS Karnofsky performance status, CMV cytomegalovirus, neg negative, pos positive, CsA cyclosporine A, MTX methotrexate, MMF mycophenolate mofetil, TCD T-cell depletion, ATG anti-thymocyte globulin, GvHD graft-versus-host disease, NA not assessed, IQR interquartile range, CI confidence interval.
  2. *Statistical difference between with and without in vivo TCD. **Statistical difference between ATG vs alemtuzumab.
Back to article page